(INNF)
APRUTUMAB IXADOTINA(INNS)
APRUTUMAB IXADOTIN(SLE)
APRUTUMAB IXADOTIN(INNC)
IMMUNOGLOBULIN G1-LAMBDA1, ANTI-[HOMO SAPIENS FGFR2 (FIBROBLAST GROWTH FACTOR RECEPTOR2, KERATINOCYTE GROWTH FACTOR RECEPTOR,KGFR ,CD332)], HOMO SAPIENS MONOCLONAL ANTIBODY CONJUGATED TO AN AURISTATIN W DERIVATIVE; GAMMA1 HEAVY CHAIN (1-451) [HOMO SAPIENS VH (IGHV3- 23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) - IGHG1*01, GM17,1 (CH1 (123-220), HINGE (221-235), CH2 (236-345), CH3 (346-450),CHS K>DEL (451)) (123-451)], (225-215')-DISULFIDE WITH LAMBDA1 LIGHT CHAIN (1'-216') [HOMO SAPIENS V-LAMBDA (IGLV1-47*01 (90.70%) - IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; DIMER (231-231'':234-234'')-BISDISULFIDE; CONJUGATED, ON AN AVERAGE OF 4 LYSYL, TO N-(5-CARBOXYPENTYL)-N-DEMETHYLAURISTATIN W (AW) C^1.5-(1,2-OXAZINAN-2-YL) DERIVATIVE, RECOMMENDED INN: LIST 77(WHO)
APRUTUMABUM IXADOTINUM(INN)